Tech Insider
pfizer

AP

  • Pfizer is in early talks to acquire cancer-focused biotech Seagen, The Wall Street Journal reported.
  • Seagen shares surged almost 11%, while Pfizer's slipped on Monday after the report.
  • The potential deal would likely top the cancer drugmaker's $30 billion market value.

Drug giant Pfizer is in early talks to buy cancer-focused biotech Seagen  in what could be a multibillion-dollar deal, The Wall Street Journal has reported. 

Tags
Markets, MI Exclusive, Stocks, pfizer, Seagen, Biotech stock, m&a, Aquisitions, Biotech, Cancer Treatments, stock prices, Stock Market Today, drugmakers, Cancer
Source
Seagen's stock surges almost 11% after a report that Pfizer is in talks to buy …